Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eloxx Pharmaceuticals Inc (NQ: ELOX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 13, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Eloxx Pharmaceuticals Inc Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates April 16, 2024 From Eloxx Pharmaceuticals Via GlobeNewswire Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases March 13, 2024 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update November 13, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 8/30 August 30, 2023 Via Investor Brand Network Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 4/10 April 10, 2023 Via Investor Brand Network Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria October 09, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules September 19, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome September 18, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013 September 07, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update August 14, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome August 14, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement August 03, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire This Small Cap Stock Surged Over 100% July 12, 2023 Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer. Via MarketBeat Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit July 10, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02 June 28, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome June 21, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress June 21, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement June 06, 2023 Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study May 24, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update May 15, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013 May 02, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update April 03, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013 March 28, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference March 06, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed February 27, 2023 Topline results expected in first half of 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome January 25, 2023 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces Reverse Stock Split Effective December 01, 2022 ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update November 10, 2022 From Eloxx Pharmaceuticals Via GlobeNewswire Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome November 01, 2022 Trial sites now open in Australia and the United Kingdom From Eloxx Pharmaceuticals Via GlobeNewswire Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D September 17, 2021 Via FinancialNewsMedia Topics Death Exposures Death Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.